N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide
C22H23FN4O3S — CID 155464272
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide
N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide (PubChem CID 155464272) has the molecular formula C22H23FN4O3S and a molecular weight of 442.52 g/mol. Its IUPAC name is N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide.
Molecular Properties
| Compound Name | N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide |
|---|---|
| PubChem CID | 155464272 |
| Molecular Formula | C22H23FN4O3S |
| Molecular Weight | 442.52 g/mol |
| Exact Mass | 442.15 |
| IUPAC Name | N-(1-cyclopropylpyrazol-4-yl)sulfonyl-2-(4-fluoro-2-propan-2-yl-6-pyridin-3-ylphenyl)acetamide |
| SMILES | CC(C)c1cc(F)cc(-c2cccnc2)c1CC(=O)NS(=O)(=O)c1cnn(C2CC2)c1 |
| InChI | InChI=1S/C22H23FN4O3S/c1-14(2)19-8-16(23)9-20(15-4-3-7-24-11-15)21(19)10-22(28)26-31(29,30)18-12-25-27(13-18)17-5-6-17/h3-4,7-9,11-14,17H,5-6,10H2,1-2H3,(H,26,28) |
| InChIKey | JCCPKBWPLUVLMY-UHFFFAOYSA-N |
| XLogP | 3.59 |
| TPSA | 93.95 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 442.52 |
| LogP ≤ 5 | 3.59 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155464272 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.